Arm中國行政總裁:或在2025年後在香港或上海上市
《南華早報》報道,英國晶片設計公司Arm中國合資公司Arm中國行政總裁吳雄昂表示,希望在2025年後在香港或上海上市。
吳雄昂稱,中國分公司自2018年成立以來已實現5年目標,並在去年創造7億美元的收入。
Arm已重新控制Arm中國接近兩年,但吳雄昂一直無視董事會對他的罷免,吳雄昂仍然是Arm中國的法定代表人,並持有公司印章。據悉,吳雄昂最新提出訴訟,要求自己再次被任命為Arm中國董事會成員。
吳雄昂表示,曾與Arm的最高管理層就美國對華為的制裁發生衝突,認為高層不能禁制Arm中國的最大客戶,批評他們害怕政治局勢帶來的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.